NSE: INDOCO | BSE: 532612

Expensive Performer

Download real time

238.15 4.95 (2.12%)

29.12% Fall from 52W High

67,195 NSE+BSE Volume

NSE 23 Jul, 2026 3:31 PM (IST)

2,198.2

Market Cap

Above industry Median

Beta 1Year

Low volatility

Board Meeting

The next board meeting for Indoco Remedies is on 28 Jul 2026 for the purpose of Quarterly Results See details

Indoco Remedies Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for INDOCO, BSE:532612 Indoco Remedies Ltd.

Search Inside the pdf :

Indoco Remedies Ltd.

10 May 2026

238.15

2.12%

Indoco Remedies

Buy: Indoco Remedies Ltd.

Target

ICICI Direct

Q4FY26 Decent top-line growth with better-than-expected margins Revenues grew ~19/5% YoY/QoQ to 456 crore aided by ~94/58% YoY/QoQ growth in export formulations to ~ 215 crore tracking 69% growth in the Regulated Market (US & Europe). Domestic formulations on the other remained muted to ~200 crore due to unpredictable performance in acute therapies. On the operational front, GPM declined 249/261 bps YoY/QoQ to 70.4%; EBITDA margins improved to 10.5% (1065/338 bps YoY/QoQ) on the back of reduction in operating expenses. Normalisation expected from FY27- After a prolonged hiatus, exports...

Indoco Remedies Ltd. is trading above its 200 day SMA of 230.5

Indoco Remedies Ltd.

25 Jul 2025

238.15

2.12%

Indoco Remedies (INDR IN) Q1FY26 Result Update Cost...

Hold: Indoco Remedies Ltd.

Target

Prabhudas Lilladhar

Indoco Remedies' (INDR) Q1FY26 EBITDA was largely in line. Though margins and regulated sales have recovered QoQ but they are still below its historical run-rate given elevated expenses and ongoing FDA issues. The warning letter issued for both units has restricted growth, however USFDA has allowed to resume supplies from 2 out of 4 lines. The company cited other expenses to remain elevated in the near term. Our FY26/FY27E EBITDA has been cut by 811% to factor in low margins. At CMP, the stock is trading at 3.9x EV/domestic...